Q3 EPS Estimates for Zimmer Biomet Reduced by Zacks Research

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Zacks Research lowered their Q3 2025 earnings per share (EPS) estimates for shares of Zimmer Biomet in a research note issued on Monday, November 25th. Zacks Research analyst R. Department now expects that the medical equipment provider will post earnings per share of $1.95 for the quarter, down from their previous forecast of $1.98. The consensus estimate for Zimmer Biomet’s current full-year earnings is $7.99 per share. Zacks Research also issued estimates for Zimmer Biomet’s FY2025 earnings at $8.48 EPS, Q1 2026 earnings at $2.27 EPS, Q2 2026 earnings at $2.34 EPS, Q3 2026 earnings at $2.20 EPS and FY2026 earnings at $9.13 EPS.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, meeting the consensus estimate of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The company had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.80 billion. During the same quarter last year, the company earned $1.65 EPS. Zimmer Biomet’s revenue for the quarter was up 4.1% compared to the same quarter last year.

A number of other equities analysts have also recently commented on ZBH. TD Cowen reduced their price target on Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating for the company in a report on Friday, September 6th. Wells Fargo & Company lifted their price target on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. JPMorgan Chase & Co. reduced their price target on Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating for the company in a report on Monday, September 16th. Robert W. Baird reduced their price target on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating for the company in a report on Thursday, August 8th. Finally, Royal Bank of Canada boosted their price objective on Zimmer Biomet from $120.00 to $125.00 and gave the stock an “outperform” rating in a report on Monday, November 4th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus price target of $123.22.

Zimmer Biomet Trading Up 1.3 %

Zimmer Biomet stock opened at $112.06 on Wednesday. Zimmer Biomet has a 52 week low of $101.47 and a 52 week high of $133.90. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. The stock has a market capitalization of $22.31 billion, a P/E ratio of 21.30, a PEG ratio of 2.04 and a beta of 1.02. The stock has a 50-day simple moving average of $107.07 and a 200 day simple moving average of $109.49.

Institutional Investors Weigh In On Zimmer Biomet

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. American Century Companies Inc. raised its position in Zimmer Biomet by 12.6% during the second quarter. American Century Companies Inc. now owns 6,463,845 shares of the medical equipment provider’s stock valued at $701,521,000 after purchasing an additional 722,041 shares in the last quarter. Geode Capital Management LLC raised its position in Zimmer Biomet by 2.6% during the third quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock valued at $524,942,000 after purchasing an additional 125,852 shares in the last quarter. Van ECK Associates Corp raised its position in Zimmer Biomet by 12.4% during the third quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider’s stock valued at $391,239,000 after purchasing an additional 411,163 shares in the last quarter. Victory Capital Management Inc. raised its position in Zimmer Biomet by 6.7% during the second quarter. Victory Capital Management Inc. now owns 3,364,624 shares of the medical equipment provider’s stock valued at $365,163,000 after purchasing an additional 211,637 shares in the last quarter. Finally, Boston Partners raised its position in Zimmer Biomet by 26.3% during the first quarter. Boston Partners now owns 3,314,939 shares of the medical equipment provider’s stock valued at $437,413,000 after purchasing an additional 691,191 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.